Patent foramen ovale and migraine: Evidence for a link?

Headache Currents

Volumn 3, Issue 2, 2006, Pages 44-51

  Bousser, Marie Germaine ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Decompression illness; Ischemic stroke; Migraine; Patent foramen ovale

Indexed keywords

ANTIMIGRAINE AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; DECOMPRESSION SICKNESS; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; HEADACHE; HEART ATRIUM SEPTUM DEFECT; HEART SURGERY; HUMAN; LUNG FUNCTION; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PARADOXICAL EMBOLISM; PATHOLOGICAL ANATOMY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPREADING CORTICAL DEPRESSION; SYMPTOM; THROMBOCYTE AGGREGATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 33646161241     PISSN: 17435005     EISSN: 17435013     Source Type: Journal    
DOI: 10.1111/j.1743-5013.2006.00030.x     Document Type: Review

References (64)

1. Bousser MG, Welch KMA. Relation between migraine and stroke. Lancet Neurol 2005; 4: 533-542.
2. Haas DC. Arteriovenous malformations and migraine: Case reports and an analysis of the relationship. Headache 1991; 31: 509-513.
3. Pavlakis SG, Phillips PC, Di Mauro S, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: A distinct clinical syndrome. Ann Neurol 1984; 16: 481-488.
4. Vahedi K, Chabriat H, Levy C, et al. Migraine with aura and brain magnetic resonance imaging in patients with CADASIL. Arch Neurol 2004; 61: 1237-1240.
5. Olesen J, Friberg L, Olsen TS, et al. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain 1993; 116: 187-202.
6. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation 2005; 112: 1063-1072.
7. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004; 24: 1-160.
8. Haerter K, Ayata C, Moskowitz MA. Cortical spreading depression: A model for understanding migraine biology and future drug targets. Headache Currents 2005; 2: 97-103.
9. Troost BT, Mark LE, Maroon JC. Resolution of classic migraine after removal of an occipital lobe arteriovenous malformation. Ann Neurol 1979; 5: 199-201.
10. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148-1152.
11. Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet 1988; 2: 11-12.
12. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 2000; 55: 1172-1179.
13. Meissner I, Khanderia BK, Heit, et al. Patent foramen ovale: Innocent or guilty?Evidence from a prospective, population-based study. J Ann Coll Cardiol 2006; 47: 440-445.
14. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, For the PFO in Cryptogenic Stroke Study (PICSS) investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale in cryptogenic stroke study. Circulation 2002; 105: 2625-2631.
15. Schreiter SW, Phillips JH. Thromboembolus traversing a patent foramen ovale: Resolution with anticoagulation. J Am Soc Echocardiogr 1994; 7: 659-662.
16. Hust MH, Staiger M, Braun B. Migration of paradoxical embolus through a patent foramen ovale diagnosed by echocardiography: Successful thrombolysis. Am Heart J 1995; 129: 620-622.
17. Berthet K, Lavergne T, Cohen A, et al. Signifiant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 2000; 31: 398-403.
18. Maisel WH, Laskey WK. Patent foramen ovale closure devices. Moving beyond equipoise. JAMA 2005; 294: 366-369.
19. Messe SR, Silverman IE, Kizer JR, et al. for the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Recurrent stroke with patent foramen ovale and atrial septal aneurysm: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 62: 1042-1050.
20. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ 2005; 330: 63-65.
21. Sztajzel R, Genoud D, Roth S, Mermillod B, Floch-Rohr J. Patent foramen ovale, a possible cause of symptomatic migraine: A study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002; 13: 102-106.
22. Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: A case-control study. Cerebrovasc Dis 1998; 8: 327-330.
23. Anzola GP, Magni M, Guindani M, Rozzini L, Dalla VG. Potential source of cerebral embolism in migraine with aura: A transcranial Doppler study. Neurology 1999; 52: 1622-1625.
24. Carerj S, Narbone MC, Zito C, et al. Prevalence of atrial septal aneurysm in patients with migraine: An echocardiographic study. Headache 2003; 43: 725-728.
25. Angeli S, Carrera P, Del Sette M, et al. Very high prevalence of right-to-left shunt on transcranial Doppler in an Italian family with cerebral autosomal dominant arteriopathy with surbortical infarcts and leukoencephalopathy. Eur Neurol 2001; 46: 198-201.
26. Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: The PFO-ASA study. Stroke 2002; 33: 706-711.
27. Engel GL, Webb JP, Ferris EB, Romano J, Ryder H, Blankenhorn MA. A migraine like syndrome complicating decompression sickness. War Medicine 1944; 5: 304-314.
28. Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary righ-to-left shunts. Clin Sci 2001; 100: 215-220.
29. Wilmshurst PT, Pearson MJ, Nightingale S. Reevaluation of the relationship between migraine and persistent foramen ovale and other right-to-left shunts. Clinical Science 2005; 108: 365-367.
30. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000; 356: 1648-1651.
31. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: A new migraine treatment? J Interv Cardiol 2003; 16: 39-42.
32. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004; 62: 1399-1401.
33. Post MC, Thijs V, Herroelen L, Budts W. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004; 62: 1439-1440.
34. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches. Impact of transcatheter closure. J Am Coll Cardiol 2005; 45: 489-492.
35. Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005; 45: 493-495.
36. Limmroth V, Katsarava Z, Kiener HC. Acetylsalieylic acid in the treatment of headache. Cephalalgia 1999; 19: 545-551.
37. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 2005; 91: 1173-1175.
38. Bousser MG, Conard J, Lecrubier C, Bousser J. Migraine ou accidents ischémiques transitoires au cours d'une thrombocytémie essentielle?Action de la Ticlopidine. Ann Med Intern 1980; 131: 87-90.
39. Fisher CM. Migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neuro Sci 1980; 7: 9-17.
40. Jauss M, Schleime C, Hügens-Penzel M, Traupe H, Kaps M. Disclosure of paradoxical brain embolism in two stroke patients with ultrasound test for right-to-left shunt and diffusion-weighted MRI. Cerebrovasc Dis 2002; 14: 267-269.
41. Yankovsky AE, Kuritzky A. Transformation into daily migraine with aura following transcutaneous atrial septal defect closure. Headache 2003; 43: 496-498.
42. Riederer F, Kaya M, Plank C, Gabriel H, Wessely P. Migraine with aura related to closure of atrial septal defects. Headache 2005; 45: 953-956.
43. Van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia 2002; 22: 265-270.
44. Mortelmans K, Post M, Thijs V, Herroelen L, Budts W. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 2005; 26: 1533-1537.
45. Wilmshurst PT, Pearson MJ, Nightingale S, Walsh KP, Morrison WL. Inheritance of patent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart 2004; 90: 1315-1320.
46. Wilmshurst PT. The persistent foramen ovale and migraine. Rev Neurol (Paris) 2005; 161: 671-674.
47. Chabriat H, Pappata S, Traykov L, et al. Angiomatose de Sturge-Weber responsable d'une hémiplégie sans infarctus cerebral en fin de grossesse. Rev Neurol 1996; 152: 536-541.
48. Steele JG, Nath PU, Burn J, et al. An association between migrainous aura and hereditary hemorrhagic telangiectasia. Headache 1993; 33: 145-148.
49. Ratinahirana H, Benigni JP, Bousser MG. Injection of polidocanol foam (PF) in varicose veins as a trigger for attacks of migraine with visual aura. Cephalalgia 2003; 23: 850-851.
50. Fragoso YD. Reduction of migraine attacks during the use of warfarin. Headache 1997; 37: 667-668.
51. Van Puijenbroek EP, Egberts JF, Trooster JFG, Zomerdijk J. Reduction of migrainous headaches during the use of acenocoumarol. Headache 1996; 36: 48.
52. Morales-Asin F, Iniguez C, Cornudella R, Mauri JA, Espada F, Mostacero E. Patients with acenocoumarol treatment and migraine. Headache 2000; 40: 45-47.
53. Kruit MC, Van Buchem MA, Hofman PAM. Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 291: 427-434.
54. Kruit MC, Launer LJ, Ferrari MD, Van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 2005; 128: 2068-2077.
55. Heckmann JG, Lang CJG, Dietrich W, Neidhardt B, Neunförfer B. Symptomatic migraine linked to stroke due to paradoxical embolism and elevated thrombosis risk. Cephalalgia 2002; 22: 154-156.
56. Ago T, Ooboshi H, Kitazono T, et al. Brain infarction associated with antiphospholipid antibody syndrome caused by paradoxical embolism throught patent foramen ovale. J Neurol 2004; 251: 757-759.
57. Giardini A, Donti A, Formigari R, et al. Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with-vs-without thrombophilia. Am J Cardiol 2004; 94: 1012-1016.
58. Soriani S, Borgna-Pignatti C, Trabetti E, et al. Frequency of factor V Leiden in juvenile migraine with aura. Headache 1998; 38: 779-781.
59. Crassard I, Conard J, Bousser MG. Migraine and haemostasis. Cephalalgia 2001; 21: 630-636.
60. Damasio H, Beck D. Migraine, thrombocytopenia and serotonin metabolism. Lancet 1978; 2: 240-241.
61. Milhaud D, Bogousslavsky J, Van Melle G, Liot P. Ischemic stroke and active migraine. Neurology 2001; 57: 1805-1811.
62. Hedman C, Andersen AR, Andersson PG, et al. Symptoms of classic migraine attacks: Modification brought about by metoprolol. Cephalalgia 1988; 8: 279-284.
63. Messé SR, Cucchiara B, Luciano J, Kasner SE. PFO management: Neurologists vs cardiologists. Neurology 2005; 65: 172-173.
64. Landzberg MJ, Khairy P. Indications for the closure of patent foramen ovale. Heart 2004; 90: 219-224.